Citations

Clear

1526 citation(s) found for "Sun, Yu".

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Montagna, Giacomo , Mrdutt, Mary M., Hlavin, Callie , Diego, Emilia J. , Wong, Stephanie M. , Barrio, Andrea V. , Bruele, Astrid Botty van den , Cabıoğlu, Neslihan , Sevilimedu, Varadan , Hwang, E. Shelley, Ingham, Abigail, Papassotiropoulos, Bärbel , Nguyen-Sträuli, Bich Doan , Kurzeder, Christian , Aybar, Danilo Díaz, Vorburger, Denise , Matlac, Dieter Michael, Fitzal, Florian , Meani, Francesco , Fick, Franziska, Sagasser, Jacqueline, Heil, Jörg, Dedes, Konstantin J. , Romics, László , Banys‐Paluchowski, Maggie , Müslümanoğlu, Mahmut , Pérez, María del Rosario Cueva, Díaz, Marcelo Chávez , Heidinger, Martin , Fehr, Mathias K. , Tükenmez, Mustafa , Maggi, Nadia , Ditsch, Nina , Zarhi, Sebastián Solé, Küemmel, Sherko , Bruz̆as, S., Lascio, Simona Di , Parissenti, Tamara K., Güth, Uwe , Ovalle, Valentina , Tausch, Christoph, Kuerer, Henry M. , Caudle, Abigail S. , Boileau, Jean-François , Kühn, Thorsten, Morrow, Monica , Weber, William P. , Hoskin, Tanya L. , Heidinger, Martin , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Sun, Susie X. , Rosenberger, Laura H. , Matlac, Dieter Michael , Ostapenko, Edvin , Riedel, Fabian , Heil, Jörg, Karanlık, Hasan , Reinisch, Mattea , Rocco, Nicola , Gentilini, Oreste D , Paulinelli, Régis Resende , Boughey, Judy C.

Mayo Clinic

JAMA Oncology | April 25, 2024 | Volume: 10 | Issue: 6 | Pages: 793

10.1001/jamaoncol.2024.0578 | PMID 38662396 Get It

ImportanceData on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown.ObjectiveTo investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node.Design, Setting, and ParticipantsIn this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis.ExposureOmission of ALND after SLNB or TAD.Main Outcomes and MeasuresThe primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed.ResultsA total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)–positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P < .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P < .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55).Conclusions and RelevanceThe results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.
Reduced Expression of CLEC4G in Neurons Is Associated with Alzheimer’s Disease
Feng, Xinwei , Huang, Yuying , Zhang, Ge , Deng, Wenbin , Deng, Wenbin , Qi, Fangfang

Mayo Clinic

International Journal of Molecular Sciences | April 24, 2024 | Volume: 25 | Issue: 9 | Pages: 4621

10.3390/ijms25094621 | PMID 38731839 Get It

CLEC4G, a glycan-binding receptor, has previously been demonstrated to inhibit Aβ generation, yet its brain localization and functions in Alzheimer’s disease (AD) are not clear. We explored the localization, function, and regulatory network of CLEC4G via experiments and analysis of RNA-seq databases. CLEC4G transcripts and proteins were identified in brain tissues, with the highest expression observed in neurons. Notably, AD was associated with reduced levels of CLEC4G transcripts. Bioinformatic analyses revealed interactions between CLEC4G and relevant genes such as BACE1, NPC1, PILRA, TYROBP, MGAT1, and MGAT3, all displaying a negative correlation trend. We further identified the upstream transcriptional regulators NR2F6 and XRCC4 for CLEC4G and confirmed a decrease in CLEC4G expression in APP/PS1 transgenic mice. This study highlights the role of CLEC4G in protecting against AD progression and the significance of CLEC4G for AD research and management.
Abstract 9881: Safety of Bariatric Surgery in Obese Patients with Hypertrophic Cardiomyopathy
Sun, Daokun , McKenzie, Travis J. , Ommen, Steve R. , Schaff, Hartzell V. , Nishimura, Rick A. , Geske, Jeffrey B. , Dearani, Joseph A.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9881 Get It

Introduction: Obesity is an independent risk factor for heart failure in patients with hypertrophic cardiomyopathy (HCM). Bariatric surgery is associated with improved cardiac function in obese patients with heart failure, but the safety of this procedure has not been evaluated in HCM patients. In this study, we examined national trends and early outcomes in bariatric surgery for patients with HCM. Methods: Using the weighted discharge data from the National Inpatient Sample, we identified adult patients with HCM who underwent elective bariatric surgery for obesity between 2011 and 2017. Patients with a history of bariatric surgery or having malignant neoplasms in the esophagus, stomach, small intestine, or pancreas were excluded. Results: A total of 443 obese patients with HCM were identified, and 41.8% (n=185) had obstructive HCM. The annual number of patients increased from 18 in 2011 to 130 in 2017, and nearly half of the patients (48%) had bariatric surgery in 2016 and 2017. Overall, the median (IQR) age was 50 (43-57) years, and 85 (19%) patients were 60 years or older. Approximately 20% (n=90) of the patients had heart failure at the time of operation. Atrial fibrillation was present in 83 (19%) patients, and 22% (n=95) of the cohort had a pacemaker or automatic cardiac defibrillator implanted prior to the operation. Laparoscopic sleeve gastrectomy (72%, n=318) and laparoscopic Roux-en-Y gastric bypass (25%, n=110) were the most commonly performed bariatric procedures. Overall, patients stayed in hospital for a median (IQR) of 2 (1-2) days. During the hospital stay, 1% (n=5) of the patients had acute worsening of chronic heart failure, but there were no deaths, cardiac arrests, or cerebrovascular accidents post procedure. Conclusions: Bariatric surgery in patients with HCM is performed more frequently in recent years and is safe and associated with few perioperative complications. Given the impact of obesity on long-term survival, clinicians should strongly consider bariatric surgery for HCM patients who do not respond to conservative weight loss measures.
Persistent Inequities in Intravenous Thrombolysis for Acute Ischemic Stroke in the United States: Results From the Nationwide Inpatient Sample
Sun, Philip Y. , Zheng, Ling , Lin, Michelle , Cen, Steven , Hammond, Gmerice, Maddox, Karen E. Joynt , Kim‐Tenser, May , Sanossian, Nerses , Mack, William J. , Towfighi, Amytis , Sun, Philip , Joynt Maddox, Karen E , Mack, William , Lin, Michelle P

Mayo Clinic

Journal of the American Heart Association | April 19, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.033316 | PMID 38639371 Get It

Background Despite its approval for acute ischemic stroke >25 years ago, intravenous thrombolysis (IVT) remains underused, with inequities by age, sex, race, ethnicity, and geography. Little is known about IVT rates by insurance status. Methods and Results We assessed temporal trends from 2002 to 2015 in IVT for acute ischemic stroke in the Nationwide Inpatient Sample using adjusted, survey ‐ weighted logistic regression. We calculated odds ratios for IVT for each category in 2002 to 2008 (period 1) and 2009 to 2015 (period 2). IVT use for acute ischemic stroke increased from 1.0% in 2002 to 6.8% in 2015 (adjusted annual relative ratio, 1.15). Individuals aged ≥85 years had the most pronounced increase during 2002 to 2015 (adjusted annual relative ratio, 1.18) but were less likely to receive IVT compared with 18‐ to 44‐year‐olds in period 1 (adjusted odds ratio [aOR], 0.23) and period 2 (aOR, 0.36). Women were less likely than men to receive IVT, but the disparity narrowed over time (period 1: aOR, 0.81; period 2: aOR, 0.94). Inequities in IVT resolved for Hispanic individuals in period 2 (aOR, 0.96) but not for Black individuals (period 2: aOR, 0.81). The disparity in IVT for Medicare patients, compared with privately insured patients, lessened over time (period 1: aOR, 0.59; period 2: aOR, 0.75). Patients treated in rural hospitals remained less likely to receive IVT than in urban hospitals; a more dramatic increase in urbanity widened the inequity (period 2, urban nonteaching versus rural: aOR, 2.58, period 2, urban teaching versus rural: aOR, 3.90). Conclusions IVT for acute ischemic stroke increased among adults. Despite some encouraging trends, the remaining disparities highlight the need for intensified efforts at addressing inequities.
Conjugal Synucleinopathies: A Clinicopathologic Study
Adler, Charles H. , Halverson, Matthew , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Driver-Dunckley, Erika, Beach, Thomas G , Adler, C H , Zhang, Nan , Driver‐Dunckley, Erika , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders | April 10, 2024 | Volume: 39 | Issue: 7 | Pages: 1212-1217

10.1002/mds.29783 | PMID 38597193 Get It

AbstractBackgroundWhile preclinical studies have shown that alpha‐synuclein can spread through cell‐to‐cell transmission whether it can be transmitted between humans is unknown.ObjectivesThe aim was to assess the presence of a synucleinopathy in autopsied conjugal couples.MethodsNeuropathological findings in conjugal couples were categorized as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease with Lewy bodies (ADLB), incidental Lewy body disease (ILBD), or no Lewy bodies.ResultsNinety conjugal couples were included; the mean age of death was 88.3 years; 32 couples had no Lewy bodies; 42 couples had 1 spouse with a synucleinopathy: 10 PD, 3 DLB, 13 ADLB, and 16 ILBD; 16 couples had both spouses with a synucleinopathy: in 4 couples both spouses had PD, 1 couple had PD and DLB, 4 couples had PD and ADLB, 2 couples had PD and ILBD, 1 couple had DLB and ADLB, in 3 couples both had ADLB, and 1 couple had ADLB and ILBD. No couples had both spouses with ILBD.ConclusionsThis large series of 90 autopsied conjugal couples found 16 conjugal couples with synucleinopathies, suggesting transmission of synucleinopathy between spouses is unlikely. © 2024 International Parkinson and Movement Disorder Society.
Conjugal Synucleinopathies: A Clinicopathologic Study (P7-3.014)
Halverson, Matthew , Chiu, Shannon , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Adler, Charles H. , Zhang, Nan , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204916 Get It

Neuropathological Profile of Cases with Mild Cognitive Impairment (S1.009)
Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G. , Ho, Andrew Fu Wah , Choudhury, Parichita , Adler, Charles H. , Shprecher, David , Serrano, Geidy E. , Atri, Alireza , Tremblay, Cécilia

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204810 Get It

Retain and Adapt: Online Sequential EEG Classification With Subject Shift
Duan, Tiehang , Wang, Zhenyi , Shen, Li , Doretto, Gianfranco , Adjeroh, Donald , Li, Fang , Tao, Cui , Tao, Cui , Li, Fang , Shen, Li

Mayo Clinic

IEEE Transactions on Artificial Intelligence | April 5, 2024 | Volume: 5 | Issue: 9 | Pages: 4479-4492

10.1109/tai.2024.3385390 Get It

CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2
Jones, Jeremy , Shen, Lin , Bai, Yuxian , Deng, Yanhong , Yang, Zhao, Schelman, William R., Qin, Shukui , Jones, Jeremy C , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , García‐Carbonero, Rocio , Masuishi, Toshiki , Cremolini, Chiara , Ghiringhelli, François , Hubbard, Joleen M. , Bekaii‐Saab, Tanios , Xu, Rui‐Hua , Xu, Jianming , Yuan, Ying , Wei, Wei , Lin, Jianchang , Chen, Lucy L , Li, Jin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 5, 2024 | Volume: 22 | Issue: 2.5 | Pages: No page available

10.6004/jnccn.2023.7171 Get It

Abstract LB249: Multi-omics cancer risk assessment of Barrett’s esophagus with DNA methylation sequencing from endoscopic brush samples
Matchett, Caroline L. , Taylor, William R. , Wang, Panwen , Anderson, Caryn E., Passe, Melissa, Lansing, Ramona, Chalmers, Collin E., Passow, Jeanette E. Eckel, Mahoney, Doug W., Iyer, Prasad G. , Sun, Zhifu , Slettedahl, Seth W. , Berger, Calise K. , Foote, Patrick H. , Kisiel, John B.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: LB249-LB249

10.1158/1538-7445.am2024-lb249 Get It

Abstract Introduction: Barrett’s esophagus (BE) confers increased cancer risk. Endoscopic surveillance is recommended to distinguish non-dysplastic BE (NDBE), low grade dysplasia (LGD), high grade dysplasia (HGD), or adenocarcinoma (EAC) for endoscopic intervention. However, this paradigm is limited by sampling error, leading to missed/interval EAC. Herein, we aimed to classify these samples more accurately by performing whole genome methylation sequencing (WGMS) and utilizing multiple genomic features on endoscopic brush samples. Materials and methods: Endoscopic brush samples from patients with NDBE (n=18), HGD (18), EAC (18), and normal controls (18) were collected and underwent WGMS (discovery dataset). Sequence reads were processed through internal pipeline to extract CpG methylation and read level methylation ratio (alpha value). Copy number aberration (CNA) detection was performed using both CNVkit and ichorCNA. Differential methylated regions (DMRs) were identified through comparing EAC/HGD with NDBE and normal samples. Targeted methylation sequencing for selected DMRs and shallow WGMS were performed on EAC (41), HGD (26), LGD (23), NDBE (42), and normal controls (37) as validation. Ratio of the reads with alpha value>0.6 for each DMR was used for further analysis. Detected CNA segments were summarized into chromosome arm loss or gain (aneuploidy score or AS representing the number of chromosome arms gained or lost in a sample) and trimmed median absolute deviation (tMAD). Classification models were developed using the discovery set and the best performing one was applied to the validation dataset. Results: Genome-wide DNA methylation largely segregated different groups of samples as diagnosed; however, some unexpected group crossings were observed. Top 200 DMRs were identified between EAC/HGD and NDBE and normal samples. CNA changes were widespread in EAC, very common in HGD but rare in NDBE (17/18 EACs,14/18 HGDs, 5/18 NDBEs with AS>0). With tMAD > 0.015, 16/18 EACs, 8/18 HGDs but none of 18 NDBEs passed the threshold. EAC or HGD samples without detectable CNAs had very low “tumor” fraction as determined by methylation-based cell type deconvolution or ichorCNA. Similar results were found in the validation dataset. A multi-omics (AS, tMAD, estimated tumor fraction, and DMR methylation) model could predict EAC, HGD, or NDBE with 0.81 accuracy through cross validation (10X) and 0.73 in the independent dataset. This increased to 0.98 and 0.90 in separating high risk EAC/HGD from NDBE, respectively. Conclusion: Multi-omics data obtained from single WGMS allow for a comprehensive analysis of BE samples with varying dysplasia levels. Using classification modeling, these characteristics can be effectively used to accurately identify and distinguish between EAC and HGD from NDBE, suggesting their utility as adjuncts to endoscopic surveillance biopsies. Citation Format: Zhifu Sun, Caroline L. Matchett, Seth W. Slettedahl, William R. Taylor, Panwen Wang, Calise Berger, Caryn E. Anderson, Melissa A. Passe, Ramona Lansing, Collin E. Chalmers, Patrick H. Foote, Jeanette E. Eckel Passow, Doug W. Mahoney, John B. Kisiel, Prasad G. Iyer. Multi-omics cancer risk assessment of Barrett’s esophagus with DNA methylation sequencing from endoscopic brush samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB249.